Docusate
Docusate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| basic care stool softener | C200263 | 2024-06-14 |
| betr remedies stool softener | C200263 | 2024-10-30 |
| calming days vegan sunscreen | C200263 | 2025-01-08 |
| chupanzon colon detox | C200263 | 2023-11-16 |
| citranatal 90 dha | unapproved drug other | 2024-01-08 |
| citranatal assure | unapproved drug other | 2024-01-08 |
| citranatal bloom dha | unapproved drug other | 2020-04-06 |
| citranatal dha | unapproved drug other | 2020-07-28 |
| citranatal essence | unapproved drug other | 2020-07-07 |
| citranatal harmony | unapproved drug other | 2012-01-18 |
Show 123 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
709 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Streptococcal infections | D013290 | EFO_1001476 | — | — | — | 1 | — | — | 1 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 1 | — | — | — | 1 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | — | — | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Docusate |
| INN | docusate sodium |
| Description | 1,4-bis(2-ethylhexyl) sulfosuccinate is a diester and an organosulfonic acid. |
| Classification | Small molecule |
| Drug class | Stool softener |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 10041-19-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1477036 |
| ChEBI ID | 534 |
| PubChem CID | 11339 |
| DrugBank | DB11089 |
| UNII ID | F05Q2T2JA0 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Docusate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Docusate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 79,899 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal 90 dha, Citranatal assure, Citranatal dha, Citranatal essence, Citranatal harmony, Citranatal harmony 2.1, Citranatal harmony 3.0, Citranatal rx, Ferralet 90, Prenaissance, Prenaissance plus, Prenate pixie
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,119 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use